University of California, San Francisco
San Francisco, United States
Publications on this disease35
Research view
Switch to patient viewAcute myeloid leukaemia: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- FLT3 36
- TP53 9
- NPM1 27
- IDH 29
- KMT2A 20
- RUNX1 2
- CD123 19
- BCL-2 10
- ABL1 2
- CD33 17
- PI3K 3
- mTOR 0
- KIT 3
- JAK 1
- CD19 8
- MAPK 0
- STAT3 0
- ERK 0
- AKT 0
- CD38 6
- HDAC 2
- MYC 1
- NRF2 0
- PD-1 4
- PPAR 0
- CXCR4 0
- BRD4 0
- PD-L1 0
- RAS 0
- STING 1
- HIF-1 0
- TIM-3 0
- METTL3 0
- CD47 1
- CTNNB1 0
- JNK 0
- KRAS 0
- MEK 0
- PARP 3
- EZH2 0
- IL-6 2
- BRAF 0
- EGFR 0
- FTO 0
- HSP90 0
- PDGFR 0
- PTEN 0
- CDK4/6 0
- FGFR 2
- GPX4 0
- HMGB1 0
- NLRP3 0
- NRAS 0
- SHP2 0
- AMPK 0
- CD20 1
- IL-15 1
- MDM2 0
- PINK1 0
- PKM2 0
1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NCI · F31
Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia
NIH NCI · R01
Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis
NIH NINDS · R03
Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion
NIH NCI · R56
NIH NCI · R21
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)
European Commission (Horizon Europe) · HORIZON-ERC
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
European Commission (Horizon Europe) · HORIZON-ERC
European Commission (Horizon Europe) · HORIZON-ERC
Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)
The disease is named only in the funder's project summary, not in the title.
10 of 499 running projects, newest first. Listed amounts together: US$328.5m + €53.2m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Withdrawn
“Sponsor decision.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 39
- Mendelian Randomization Analysis 3
- CRISPR-Cas Systems 17
- Gene Expression Profiling 85
- Sequence Analysis, RNA 6
- Whole Genome Sequencing 7
- Exome Sequencing 1
- Proteomics 28
- Metabolomics 10
- Mass Spectrometry 3
- Flow Cytometry 88
- Immunohistochemistry 14
- Liquid Biopsy 1
- Circulating Tumor DNA 3
- Xenograft Model Antitumor Assays 160
- Positron-Emission Tomography 1
- Magnetic Resonance Imaging 11
- Machine Learning 33
- Deep Learning 12
- Cohort Studies 30
- Genome-Wide Association Study 3
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.